AI cardiology group Ultromics gears up for US growth with £40m round
AI-powered cardiology diagnostics company Ultromics has secured a $55m (£41.4m) Series C funding round to fuel its expansion across the US. Founded in Oxford in 2017, Ultromics develops AI technology to support clinicians in the detection of particularly elusive forms of heart failure. According to research cited by the company, Heart Failure with Preserved Ejection Fraction (HFpEF), among the forms detected by its technology, goes diagnosed in up to 64% of cases. “The reality is, hospitals already have the data, they just haven’t had the tools to extract diagnostic signals from it,” said Ross Upton, Ultromics founder and chief executive. “By analysing routine echocardiograms with AI, we’re helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses.” The company is gearing up for significant scaling in the US, with its technology having already received clearance from the Food and Drug Administration (FDA) and eligibility for Med...